BMS-540215 Brivanib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：BMS-540215 Brivanib	Purity：98% min
CAS NO：649735-46-6	Solubility：DMSO : ≥ 50 mg/mL (135.00 mM)
Molecular Formula：C₁₉H₁₉FN₄O₃	Package：Package according to customer requirements.
Molecular Weight：370.378	Storage：Store at -20℃

Quality control

Remarks

Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.

Related Prodcuts:

LY2874455; ZM-306416; ZM323881; Tyrphostin A9; Orantinib; Foretinib; SU5402; Semaxanib; SAR131675; Lucitanib; Apatinib; SKLB610; Altiratinib; SGI-7079; AZD2932

References

[1]. Bhide RS, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem, 2006, 49 (7), 2143-2146.

[2]. Huynh H, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008,